
USD
+$0.00
(+0.00%
)At Close (As of Oct 31, 2025)
$94.31B
Market Cap
13.3
P/E Ratio
3.53
EPS
$47.16
52 Week High
$30.68
52 Week Low
HEALTHCARE
Sector
| Field | Value (GBP) | 
|---|---|
| Gross Profit | $22B | 
| Total Revenue | $31B | 
| Cost Of Revenue | $9B | 
| Costof Goods And Services Sold | $9B | 
| Operating Income | $4B | 
| Selling General And Administrative | $11B | 
| Research And Development | $6.4B | 
| Operating Expenses | $18B | 
| Investment Income Net | - | 
| Net Interest Income | -$603M | 
| Interest Income | $60M | 
| Interest Expense | $658M | 
| Non Interest Income | - | 
| Other Non Operating Income | - | 
| Depreciation | - | 
| Depreciation And Amortization | $2.6B | 
| Income Before Tax | $3.5B | 
| Income Tax Expense | $526M | 
| Interest And Debt Expense | - | 
| Net Income From Continuing Operations | $3B | 
| Comprehensive Income Net Of Tax | - | 
| Ebit | $4.1B | 
| Ebitda | $6.7B | 
| Net Income | $2.6B | 
| Field | Value (GBP) | 
|---|---|
| Total Assets | $59B | 
| Total Current Assets | $17B | 
| Cash And Cash Equivalents At Carrying Value | $3.7B | 
| Cash And Short Term Investments | $3.7B | 
| Inventory | $5.7B | 
| Current Net Receivables | $6B | 
| Total Non Current Assets | $42B | 
| Property Plant Equipment | $10B | 
| Accumulated Depreciation Amortization Ppe | - | 
| Intangible Assets | $16B | 
| Intangible Assets Excluding Goodwill | $16B | 
| Goodwill | $7B | 
| Investments | - | 
| Long Term Investments | - | 
| Short Term Investments | $21M | 
| Other Current Assets | $1.6B | 
| Other Non Current Assets | - | 
| Total Liabilities | $46B | 
| Total Current Liabilities | $22B | 
| Current Accounts Payable | $3.5B | 
| Deferred Revenue | - | 
| Current Debt | - | 
| Short Term Debt | $2.3B | 
| Total Non Current Liabilities | $25B | 
| Capital Lease Obligations | $1.1B | 
| Long Term Debt | $14B | 
| Current Long Term Debt | $2.2B | 
| Long Term Debt Noncurrent | - | 
| Short Long Term Debt Total | $17B | 
| Other Current Liabilities | $15B | 
| Other Non Current Liabilities | $6.1B | 
| Total Shareholder Equity | $14B | 
| Treasury Stock | - | 
| Retained Earnings | $7.8B | 
| Common Stock | $1.3B | 
| Common Stock Shares Outstanding | $2.1B | 
| Field | Value (GBP) | 
|---|---|
| Operating Cashflow | $6.6B | 
| Payments For Operating Activities | - | 
| Proceeds From Operating Activities | - | 
| Change In Operating Liabilities | - | 
| Change In Operating Assets | - | 
| Depreciation Depletion And Amortization | $2.6B | 
| Capital Expenditures | $3B | 
| Change In Receivables | - | 
| Change In Inventory | -$294M | 
| Profit Loss | - | 
| Cashflow From Investment | -$1.2B | 
| Cashflow From Financing | -$4.7B | 
| Proceeds From Repayments Of Short Term Debt | - | 
| Payments For Repurchase Of Common Stock | - | 
| Payments For Repurchase Of Equity | - | 
| Payments For Repurchase Of Preferred Stock | - | 
| Dividend Payout | $2.4B | 
| Dividend Payout Common Stock | $2.4B | 
| Dividend Payout Preferred Stock | - | 
| Proceeds From Issuance Of Common Stock | - | 
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - | 
| Proceeds From Issuance Of Preferred Stock | - | 
| Proceeds From Repurchase Of Equity | $20M | 
| Proceeds From Sale Of Treasury Stock | - | 
| Change In Cash And Cash Equivalents | - | 
| Change In Exchange Rate | - | 
| Net Income | $3B | 
| Field | Value (GBP) | 
|---|---|
| Gross Profit | $22B | 
| Total Revenue | $31B | 
| Cost Of Revenue | $9B | 
| Costof Goods And Services Sold | $9B | 
| Operating Income | $4B | 
| Selling General And Administrative | $11B | 
| Research And Development | $6.4B | 
| Operating Expenses | $18B | 
| Investment Income Net | - | 
| Net Interest Income | -$603M | 
| Interest Income | $60M | 
| Interest Expense | $658M | 
| Non Interest Income | - | 
| Other Non Operating Income | - | 
| Depreciation | - | 
| Depreciation And Amortization | $2.6B | 
| Income Before Tax | $3.5B | 
| Income Tax Expense | $526M | 
| Interest And Debt Expense | - | 
| Net Income From Continuing Operations | $3B | 
| Comprehensive Income Net Of Tax | - | 
| Ebit | $4.1B | 
| Ebitda | $6.7B | 
| Net Income | $2.6B | 
| Field | Value | 
|---|---|
| Ex Dividend Date | 2025-11-14 | 
| Declaration Date | 2025-10-29 | 
| Record Date | 2025-11-14 | 
| Payment Date | 2026-01-08 | 
| Amount | 0.417088 | 
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
GlaxoSmithKline PLC (GSK) is a prominent global biopharmaceutical company headquartered in Brentford, UK, dedicated to improving health outcomes through its innovative pharmaceuticals, vaccines, and consumer healthcare products. With a focus on robust research and development, GSK aims to tackle significant global health challenges while maintaining a diverse product portfolio across multiple therapeutic areas. The company’s strategic initiatives and commitment to advancing medical science position it as a vital contributor to the global healthcare landscape, appealing to institutional investors seeking opportunities within the evolving biopharmaceutical industry.